Evidence map›Paper›PMID 34112916›Full record

ArticleCommunications biology2021

Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells.

Laetitia Seguin, Soline Odouard, Francesca Corlazzoli, Sarah Al Haddad, Laurine Moindrot, Marta Calvo Tardón, Mayra Yebra, Alexey Koval, Eliana Marinari, Viviane Bes and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Laetitia Seguin *University Côte d'Azur, CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging (IRCAN), Nice, France.
Soline Odouard *Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Francesca Corlazzoli *Laboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-8402-192X
Sarah Al HaddadLaboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Laurine MoindrotLaboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Marta Calvo TardónLaboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva, Geneva, Switzerland.
Mayra YebraDepartment of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Alexey KovalDepartment of Cell Physiology and Metabolism, Medical School, University of Geneva, Geneva, Switzerland.
Eliana MarinariLaboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Viviane BesLaboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva, Geneva, Switzerland.
Alexandre GuérinDepartment of Pathology and Immunology, Medical School, University of Geneva, Geneva, Geneva, Switzerland.ORCID 0000-0003-1166-9618
Mathilde AllardLaboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Sten IlmjärvDepartment of Pathology and Immunology, Medical School, University of Geneva, Geneva, Geneva, Switzerland.
Vladimir L KatanaevDepartment of Cell Physiology and Metabolism, Medical School, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-7909-5617
Paul R WalkerLaboratory of Immunobiology of brain tumors, Center for Translational Research in Onco-Hematology, Geneva University Hospitals, and University of Geneva, Geneva, Switzerland.
Karl-Heinz KrauseDepartment of Pathology and Immunology, Medical School, University of Geneva, Geneva, Geneva, Switzerland.
Valérie DutoitLaboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Jann N SarkariaDepartment of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7489-4885
Pierre-Yves DietrichLaboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Érika CossetLaboratory of Tumor Immunology, Department of Oncology, Center for Translational Research in Onco-Hematology, Swiss Cancer Center Léman (SCCL), Geneva University Hospitals, University of Geneva, Geneva, Switzerland. Erika.cosset@unige.ch.ORCID 0000-0001-5481-6556
University of Geneva · CHCentre National de la Recherche Scientifique · FRMayo Clinic in Arizona · USUniversity of California San Diego · US

Funding

Targeted MV-CEA as a Potent Antitumor Agent against GBMP50CA108961 · NCI · MAYO CLINIC ROCHESTER · PI O'NEILL, BRIAN PATRICK · 2004 to 2015
$22.5M
NCI NIH HHS P50 CA108961
6 · The paper itself

Abstract

Recently, we involved the carbohydrate-binding protein Galectin-3 (Gal-3) as a druggable target for KRAS-mutant-addicted lung and pancreatic cancers. Here, using glioblastoma patient-derived stem cells (GSCs), we identify and characterize a subset of Gal-3

Indexed as

AnimalsBlood ProteinsBrain NeoplasmsCell Line, TumorFemaleGalectinsGene Expression Regulation, NeoplasticGlioblastomaHumansMiceNeoplastic Stem CellsPinocytosisProtein Interaction MapsTranscriptomeTumor Cells, CulturedBlood ProteinsGalectinsLGALS3 protein, human

Identifiers

PMID34112916
PMCPMC8192788
OpenAlexW3171871214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.